On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
2023年12月22日，Alaunos Therapeutics與首席執行官凱文·博伊爾就博伊爾的解僱簽訂了分離和釋放協議——備案
The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consulting Agreement will continue for a period of six months.
該公司和博伊爾還簽訂了諮詢協議，該協議自2024年1月1日起生效，根據該協議，博伊爾將繼續向公司提供戰略和諮詢服務。諮詢協議將持續六個月。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。